Compare Caris Life Sciences, Inc. (CAI) vs Eli Lilly and Company (LLY) Stock

Eli Lilly and Company (LLY) offers the better valuation at 85.7x trailing P/E (29.4x forward), making it the more compelling value choice. Analysts rate Caris Life Sciences, Inc. (CAI) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Eli Lilly and Company is actually cheaper at 29.4x.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +396.9%, compared to -29.1% for Caris Life Sciences, Inc. (CAI). A $10,000 investment in LLY five years ago would be worth approximately $50K today (assuming dividends reinvested). Over 10 years, the gap is even starker: LLY returned +1316% versus CAI's -29.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Eli Lilly and Company (LLY) is the lower-risk stock at 0.65β versus Caris Life Sciences, Inc.'s 1.09β — meaning CAI is approximately 68% more volatile than LLY relative to the S&P 500. On balance sheet safety, Caris Life Sciences, Inc. (CAI) carries a lower debt/equity ratio of 0% versus 2% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

Eli Lilly and Company (LLY) is the more profitable company, earning 23.5% net margin versus -66.2% for Caris Life Sciences, Inc. — meaning it keeps 23.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 38.9% versus 5.6% for CAI. At the gross margin level — before operating expenses — LLY leads at 81.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Eli Lilly and Company (LLY) trades at 29.4x forward P/E versus 62.1x for Caris Life Sciences, Inc. — 32.6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAI: 57.8% to $31.33.

In this comparison, LLY (0.5% yield) pays a dividend. CAI does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.65), 0.5% yield, +1316% 10Y return). Both have compounded well over 10 years (LLY: +1316%, CAI: -29.1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. LLY pays a dividend while CAI does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.